Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and CAG Regimen as Bridging Therapy for Advanced MDS
NCT04216355Phase 3Unknown
- Sponsor
- Fujian Medical University
- Start
- Jan 2020
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
A Phase 3 trial of azacitidine in myelodysplastic syndrome (MDS), sponsored by Fujian Medical University. Status: unknown.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04216355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04216355.